LTGO-33 is a selective, state-independent, and potent preclinical small molecule NaV1.8 inhibitor. LTGO-33 engages a novel interaction site and possesses a mechanism of action previously unreported for the treatment of pain disorders.
For research use only. We do not sell to patients.
| Name | LTGO-33 |
|---|---|
| Iupac Chemical Name | (R)-2-(4-fluoro-2-methylphenoxy)-N-(3-(S-methylsulfonimidoyl)phenyl)-5-(trifluoromethyl)nicotinamide |
| Synonyms | LTGO-33; LTGO33; LTGO 33 |
| Molecular Formula | C21H17F4N3O3S |
| Molecular Weight | 467.44 |
| Smile | FC1=CC(C)=C(OC2=NC=C(C=C2C(NC3=CC=CC([S@](=O)(C)=N)=C3)=O)C(F)(F)F)C=C1 |
| InChiKey | IIJWTXGHWFZLBF-JGCGQSQUSA-N |
| InChi | InChI=1S/C21H17F4N3O3S/c1-12-8-14(22)6-7-18(12)31-20-17(9-13(11-27-20)21(23,24)25)19(29)28-15-4-3-5-16(10-15)32(2,26)30/h3-11,26H,1-2H3,(H,28,29)/t32-/m1/s1 |
| CAS Number | 2834106-06-6 |
| Related CAS |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Off-white solid |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
Gilchrist JM, Yang ND, Jiang V, Moyer BD. Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action. Mol Pharmacol. 2024 Feb 15;105(3):233-249. doi: 10.1124/molpharm.123.000789. PMID: 38195157.